PMC:7105881 / 22104-22443 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"708","span":{"begin":85,"end":93},"obj":"Species"},{"id":"709","span":{"begin":98,"end":106},"obj":"Species"},{"id":"710","span":{"begin":226,"end":234},"obj":"Species"},{"id":"711","span":{"begin":239,"end":247},"obj":"Species"},{"id":"714","span":{"begin":326,"end":334},"obj":"Species"}],"attributes":[{"id":"A708","pred":"tao:has_database_id","subj":"708","obj":"Tax:694009"},{"id":"A709","pred":"tao:has_database_id","subj":"709","obj":"Tax:1335626"},{"id":"A710","pred":"tao:has_database_id","subj":"710","obj":"Tax:694009"},{"id":"A711","pred":"tao:has_database_id","subj":"711","obj":"Tax:1335626"},{"id":"A714","pred":"tao:has_database_id","subj":"714","obj":"Tax:694009"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"efficacy (Du et al., 2008; Zhang et al., 2014).\nA number of subunit vaccines against SARS-CoV and MERS-CoV have been developed, and these are described in detail in the next paragraphs. The targets used for the development of SARS-CoV and MERS-CoV subunit vaccines are also be discussed.\n\nPotential Targets for Development of SARS-CoV and "}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T85","span":{"begin":85,"end":93},"obj":"Disease"},{"id":"T86","span":{"begin":226,"end":234},"obj":"Disease"},{"id":"T87","span":{"begin":326,"end":334},"obj":"Disease"}],"attributes":[{"id":"A85","pred":"mondo_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A86","pred":"mondo_id","subj":"T86","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A87","pred":"mondo_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"efficacy (Du et al., 2008; Zhang et al., 2014).\nA number of subunit vaccines against SARS-CoV and MERS-CoV have been developed, and these are described in detail in the next paragraphs. The targets used for the development of SARS-CoV and MERS-CoV subunit vaccines are also be discussed.\n\nPotential Targets for Development of SARS-CoV and "}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T240","span":{"begin":48,"end":49},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"efficacy (Du et al., 2008; Zhang et al., 2014).\nA number of subunit vaccines against SARS-CoV and MERS-CoV have been developed, and these are described in detail in the next paragraphs. The targets used for the development of SARS-CoV and MERS-CoV subunit vaccines are also be discussed.\n\nPotential Targets for Development of SARS-CoV and "}

{"project":"2_test","denotations":[{"id":"32265848-18301805-36511087","span":{"begin":21,"end":25},"obj":"18301805"},{"id":"32265848-24766432-36511088","span":{"begin":41,"end":45},"obj":"24766432"}],"text":"efficacy (Du et al., 2008; Zhang et al., 2014).\nA number of subunit vaccines against SARS-CoV and MERS-CoV have been developed, and these are described in detail in the next paragraphs. The targets used for the development of SARS-CoV and MERS-CoV subunit vaccines are also be discussed.\n\nPotential Targets for Development of SARS-CoV and "}

{"project":"LitCovid-sentences","denotations":[{"id":"T135","span":{"begin":48,"end":185},"obj":"Sentence"},{"id":"T136","span":{"begin":186,"end":287},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"efficacy (Du et al., 2008; Zhang et al., 2014).\nA number of subunit vaccines against SARS-CoV and MERS-CoV have been developed, and these are described in detail in the next paragraphs. The targets used for the development of SARS-CoV and MERS-CoV subunit vaccines are also be discussed.\n\nPotential Targets for Development of SARS-CoV and "}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T422","span":{"begin":85,"end":93},"obj":"SP_10"},{"id":"T423","span":{"begin":98,"end":106},"obj":"SP_9"},{"id":"T424","span":{"begin":226,"end":234},"obj":"SP_10"},{"id":"T425","span":{"begin":239,"end":247},"obj":"SP_9"},{"id":"T426","span":{"begin":326,"end":334},"obj":"SP_10"},{"id":"T18365","span":{"begin":85,"end":93},"obj":"SP_10"},{"id":"T63775","span":{"begin":98,"end":106},"obj":"SP_9"},{"id":"T9525","span":{"begin":226,"end":234},"obj":"SP_10"},{"id":"T91816","span":{"begin":239,"end":247},"obj":"SP_9"},{"id":"T22878","span":{"begin":326,"end":334},"obj":"SP_10"}],"text":"efficacy (Du et al., 2008; Zhang et al., 2014).\nA number of subunit vaccines against SARS-CoV and MERS-CoV have been developed, and these are described in detail in the next paragraphs. The targets used for the development of SARS-CoV and MERS-CoV subunit vaccines are also be discussed.\n\nPotential Targets for Development of SARS-CoV and "}